Abstract: The present invention relates to a method for isolating extracellular vesicles using cations, and more particularly, to a method for isolating extracellular vesicles from various samples by using the affinity between the extracellular vesicles and cations. A method for isolating extracellular vesicles according to the present invention does not require expensive equipment, can be applied irrespective of sample amount, and has the advantage of being capable of efficiently isolating the extracellular vesicles while preserving the shape or characteristics thereof. Moreover, the method according to the present invention can be combined with existing isolation methods to maximize extracellular vesicle isolation efficiency, and can be applied to disease diagnosis, disease treatment, and multi-omics research using isolated extracellular vesicles, as well as to research on the properties of extracellular vesicles.

Abstract: The present invention relates to a method for isolating extracellular vesicles and, more particularly, to a method for isolating extracellular vesicles using hydrophobicity of the extracellular vesicles, and extracellular vesicles isolated using the method. When used, the method for isolating extracellular vesicles according to the present invention allows for isolating, from various animal body fluids including blood and urine or various tissues including cancer tissues, extracellular vesicles free of contamination with lipoproteins that are difficult to eliminate using a conventional method, can solve conventional problems caused by lipoprotein contamination, and is expected to be an essential technology that has a great influence on various research using extracellular vesicles isolated from various animal body fluids or tissues, such as characterization and function research, multi-omics research, excavation of novel biomarkers, diagnosis and treatment, etc.

Abstract: The analysis method for extracellular vesicles, according to the present invention, uses the size-specific separation ability of size exclusion chromatography and the properties of a probe that specifically binds with extracellular vesicles, and by using same is capable of the rapid and easy analysis of the quantity of extracellular vesicles included in a sample, analysis of the physicochemical properties of the extracellular vesicles, analysis of the kind and quantity of the components included in the extracellular vesicles, and analysis of the binding properties or affinity of the probe with respect to the components of the extracellular vesicles.

Abstract: The present invention relates to a method and composition for enhancing the cancer treatment efficacy of bacteria extracellular vesicles, and more particularly, to a method and composition for enhancing the cancer treatment efficacy of bacteria extracellular vesicles by using a single immune checkpoint inhibitor or various combinations of two or more types of immune checkpoint inhibitors. This composition exhibits a synergic effect compared to single dosage forms of the respective inhibitors and exhibits an action of alleviating adverse effects caused by high doses of the single dosage forms, and thus may be usefully utilized in the development of cancer drugs.

Abstract: An extracellular vesicle isolation method using a metal, and a method for isolating extracellular vesicles from various samples using metal affinity are disclosed. An extracellular vesicle isolation method has the advantages of not requiring costly equipment, of being able to be applied without limits on sample quantity, and of being capable of efficiently isolating extracellular vesicles while preserving the shape or properties thereof. Moreover, the method can be combined with existing isolation methods to maximize the efficiency of extracellular vesicle isolation, and can be utilized in disease diagnosis, disease treatment, multi-omics research, and extracellular vesicle property research and the like using the isolated extracellular vesicles.

Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances.

Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances.

Abstract: The present invention relates to bacteria-derived extracellular vesicles having reduced toxicity and the use thereof and, more specifically, to a pharmaceutical composition for treating or diagnosing diseases, a composition for delivering materials and a vaccine composition comprising bacterial extracellular vesicles having reduced toxicity, a method for preparing same, and the like. By using the bacterial extracellular vesicles having reduced toxicity of the present invention, in vivo or in vitro side effects can be reduced, efficacies can be increased, and thus the stability and efficacies of a therapeutic agent or a diagnostic agent, for various diseases including cancer, a drug carrier and/or a vaccine carrier can be enhanced. The bacterial extracellular vesicles having reduced toxicity and having loaded materials for disease treatment or vaccine, and a method for preparing same can he used for in vitro or in vivo treatments, drug carriers, vaccines or experiments.

Abstract: The analysis method for extracellular vesicles, according to the present invention, uses the size-specific separation ability of size exclusion chromatography and the properties of a probe that specifically binds with extracellular vesicles, and by using same is capable of the rapid and easy analysis of the quantity of extracellular vesicles included in a sample, analysis of the physicochemical properties of the extracellular vesicles, analysis of the kind and quantity of the components included in the extracellular vesicles, and analysis of the binding properties or affinity of the probe with respect to the components of the extracellular vesicles.

Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

Abstract: The present invention relates to a method for isolating extracellular vesicles using cations, and more particularly, to a method for isolating extracellular vesicles from various samples by using the affinity between the extracellular vesicles and cations. A method for isolating extracellular vesicles according to the present invention does not require expensive equipment, can be applied irrespective of sample amount, and has the advantage of being capable of efficiently isolating the extracellular vesicles while preserving the shape or characteristics thereof. Moreover, the method according to the present invention can be combined with existing isolation methods to maximize extracellular vesicle isolation efficiency, and can be applied to disease diagnosis, disease treatment, and multi-omics research using isolated extracellular vesicles, as well as to research on the properties of extracellular vesicles.

Abstract: An extracellular vesicle isolation method using a metal, and a method for isolating extracellular vesicles from various samples using metal affinity are disclosed. An extracellular vesicle isolation method has the advantages of not requiring costly equipment, of being able to be applied without limits on sample quantity, and of being capable of efficiently isolating extracellular vesicles while preserving the shape or properties thereof. Moreover, the method can be combined with existing isolation methods to maximize the efficiency of extracellular vesicle isolation, and can be utilized in disease diagnosis, disease treatment, multi-omics research, and extracellular vesicle property research and the like using the isolated extracellular vesicles.

Abstract: A method for labeling exosomes with a radioactive substance using an amine group on surfaces of the exosomes includes providing a cell-derived exosome, treating a surface of the exosome with N-hydroxysuccinimide-azadibenzocyclooctyne (NHS-ADIBO), and mixing the treated exosome with N3-introduced chelator-radioactive substance to conduct a reaction between the chelator and an amine group present on the surface of the exosome, wherein the radioactive substance is introduced inside the exosome by the above reaction. The exosomes can be stably labeled at high labeling efficiency, and the exosomes can be favorably used as an agent for nuclear medicine imaging and therapeutic imaging for confirming the biological distribution of exosomes and whether the exosomes move to target organs and target diseases in animals including a human being.

Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

Abstract: The present invention relates to cell membrane-derived nanovesicles, a method of preparing the same, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles according to the present invention may prevent the occurrence of potential side effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivery of therapeutic or diagnostic substances are removed from the nanovesicles. In addition, since the nanovesicles may be targeted to the specific types of cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues while delivery of therapeutic or diagnostic substances to untargeted sites may be inhibited.

Abstract: A method for labeling exosomes with a radioactive substance using an amine group on surfaces of the exosomes includes providing a cell-derived exosome, treating a surface of the exosome with N-hydroxysuccinimide-azadibenzocyclooctyne (NHS-ADIBO), and mixing the treated exosome with N3-introduced chelator-radioactive substance to conduct a reaction between the chelator and an amine group present on the surface of the exosome, wherein the radioactive substance is introduced inside the exosome by the above reaction. The exosomes can be stably labeled at high labeling efficiency, and the exosomes can be favorably used as an agent for nuclear medicine imaging and therapeutic imaging for confirming the biological distribution of exosomes and whether the exosomes move to target organs and target diseases in animals including a human being.

Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.

Abstract: The present disclosure relates to a method of assessing a subject's susceptibility to a vascular disease. The method may comprise providing a concentrated population of extracellular vesicles contained in a biological material obtained from a subject, processing the concentrated population to determine if the concentrated population contains a 16S rRNA sequence of Staphylococcus, and upon determining that the concentrated population contains a 16S rRNA sequence of Staphylococcus, further determining that the subject is potentially susceptible to a vascular disease.

Abstract: The present invention relates to a cancer vaccine, and specifically, to a pharmaceutical composition for treating cancer containing a nano-vehicle derived from tumor tissue, and a method for treating cancer using the nano-vehicle derived from tumor tissue, and the like. According to the present invention, a nano-vehicle antigen derived from tumor tissue indicates a high yield while having properties similar to those of an exocellular vehicle, and can be variously modified, and is thus expected to be very useful for developing the cancer vaccine.

Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.